• Gelclair^® was shown to be at least as effective as benzydamine (recommended for the treatment of oral mucositis caused by radiotherapy by MASCC guidelines) in managing pain caused by oral mucositis.

• Gelclair^® demonstrated significantly lower pain on application, possibly favouring the use of this medical device. 
• Fewer patients in the Gelclair^® group needed opiate medication; 20% with Gelclair^® vs. 37.1% with benzydamine. 
• No patients in the Gelclair^® group needed artificial feeding with nasogastric tube; 0% with Gelclair^® vs. 12.5% with benzydamine.
• Gelclair^® can be considered a convenient and valid alternative to benzydamine for symptoms control and pain relief in patients undergoing anticancer therapies causing oral mucositis.

Reference:
Flook C et al, Supportive Care in Cancer 2005; 13(6):443-4 (abs 15-098).